441 results about "Gastrointestines" patented technology

S-Beta-hydroxybutyric acid compositions for oral delivery are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and / or as a gel or suspension. By limiting added beta-hydroxybutyrate salts containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid. Beta-hydroxybutyric acid can be pure S-beta-hydroxybutyric acid or a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid.

The invention relates to a feeding intolerance burst risk early warning method and device based on multi-modal dynamic monitoring. The method comprises the steps that a gastrointestinal tract peristaltic wave image sequence under the abdominal skin surface of a patient is collected; collecting borborygmus data; collecting physical sign physiological data of the patient; monitoring behavior and posture data of the patient in real time; tracking the infinitesimal displacement and deformation of the gastrointestinal wall in the gastrointestinal tract peristaltic wave image sequence, and extracting and quantifying the speed, direction and wave crest and trough change rate of the peristaltic wave and the regularity index of the peristaltic wave; calculating a physiological deviation degree between the fusion feature at the current moment and an expected normal mode generated by the physiological feature baseline model of the patient; and inputting the physiological deviation degree, the change rate of the physiological deviation degree in the time dimension and the accumulated deviation duration into a conditional variation risk assessment model, and outputting a potential spatial distance. Through the non-invasive and highly quantified feeding intolerance risk model, the early recognition capability and clinical intervention efficiency of feeding intolerance are remarkably improved.

The invention belongs to the technical field of biological medicines, and discloses a traditional Chinese medicine composition for treating microsatellite stability (MSS) type tumors by a sensitization immune checkpoint inhibitor. The traditional Chinese medicine composition provided by the invention comprises radix scutellariae, rhizoma zingiberis, Chinese herbaceous peony, liquorice root and Chinese date, can increase CD8 + T cell infiltration, promote the CD8 + T cell to secrete cytokines and improve the immunosuppression of MSS type tumors, and further breaks through the conventional range of anti-tumor treatment of immune examination inhibitors; meanwhile, the traditional Chinese medicine composition can also improve adverse reaction of gastrointestinal tracts caused by tumor treatment by an immune examination inhibitor, and the life quality of patients is improved.

The invention discloses lactobacillus mucus YF28 and application thereof, and belongs to the technical field of microorganisms. The fermented lactobacillus mucus YF28 is separated from Hu sheep manure, is classified and named as the fermented lactobacillus mucus YF28, and has the preservation number of CCTCC (China Center For Type Culture Collection) NO: M 20252433. The fermented lactobacillus mucilaginosus YF28 has good tolerance in the gastrointestinal environment and can reach the intestinal tract to play a role. The bacterial strain has strong intestinal adhesion capacity, is easy to form a probiotic biological membrane, and is beneficial to intestinal health. The fermented lactobacillus mucus YF28 can promote peristalsis, enrich the abundance of Akkermansia bacteria and bacteriophage thereof, restore the water content of excrement to a normal level, and significantly promote intestinal health. The invention has an application prospect in the development of drugs or health-care foods with the function of relieving constipation and related gastrointestinal symptoms.

Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.

The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.

The invention belongs to the technical field of medical image processing, and provides a multi-modal medical image analysis system, medium and equipment for gastrointestinal disease recognition, and the technical scheme is as follows: extracting multi-scale texture features and structural features of a gastrointestinal endoscopy color image and a gastrointestinal endoscopy OCT depth image respectively, and fusing to obtain a cross-modal feature sequence; based on the feature sequence added with the position code, learning a spatial corresponding relation of different modal data on blood vessel morphology and gastrointestinal tract wall interlayer structure; obtaining a multi-scale global context feature sequence and a local detail feature sequence based on the aligned cross-modal blood vessel and gastrointestinal tract wall interlayer structure features, and fusing the multi-scale global context feature sequence and the local detail feature sequence to obtain fused multi-modal features; obtaining an adjusted dense deformation field based on the fused multi-modal features; and performing coarse registration and fine registration based on the adjusted dense deformation field to obtain a registered gastrointestinal endoscopy color image and a registered gastrointestinal endoscopy OCT depth image. The anti-interference capability is strong, and the data stability is high.

Systems and methods for anchoring and restraining gastrointestinal prostheses are disclosed. In various examples, the systems and methods include securing a gastrointestinal device within a patient's anatomy by extending an anti-migration anchor through a plurality of portions of the gastrointestinal device to couple together the plurality of portions of the gastrointestinal device. In some examples, the anti-migration anchor extends through tissue situated between the plurality of portions of the gastrointestinal device.

The invention discloses a magnetic control soft robot with electrical stimulation and drug release functions, and relates to the technical field of medical instruments. In the magnetic control soft robot provided by the invention, the magnetic layer is used for driving the body to move and position in the gastrointestinal tract under the driving of an external magnetic field; the electric control layer is used for supplying power and is responsible for controlling the opportunity and parameters of electric stimulation and controlling a drug release instruction; after a microneedle of the conductive hydrogel microneedle layer penetrates into tissue, nerve endings or muscle cells can be stimulated by applying a weak electric signal so as to regulate gastrointestinal motility, relieve pain and the like, a drug can be loaded in the microneedle, and when the electric signal is applied, the drug can be loaded in the microneedle by means of electromigration, electroosmosis and the like. Triggering the drug to be controllably released into the target tissue as required; the adhesive layer is used for temporarily anchoring the robot at a specific working position of the gastrointestinal tract; according to the magnetic control soft robot and the preparation method thereof, the comprehensive requirements of gastrointestinal tract disease treatment can be met.

The invention relates to the technical field of oral non-biological medicine preparations, in particular to an upatinib sustained release tablet and a preparation method thereof. The invention discloses a preparation method of an upatinib sustained-release tablet, and aims to solve the problem that the dissolution rate of the upatinib sustained-release tablet is unstable, namely, the upatinib sustained-release tablet can stably control the release of upatinib in different gastrointestinal tract environments through the synergistic cooperation of all the components of the upatinib sustained-release tablet, and the preparation method of the upatinib sustained-release tablet is relatively low in cost and easy to operate. The large-scale production is facilitated; the upatinib sustained release tablet comprises the following components in percentage by weight: 3.0%-3.5% of upatinib, 18%-19.50% of a pH regulator, 50%-55% of a filler, 17%-22% of an adhesive, 0.1%-1% of a flow aid, 1%-2% of a lubricant and 0.01%-10.9% of a coating material.

The present invention relates to a system for monitoring gastrointestinal disorders, the system including a gastrointestinal probe, at least one sensor configured to measure a patient parameter, a patient interface configured to receive input from the patient, and a processor configured to: determine a first value and a second value corresponding to a given time interval, where if the input from the patient corresponds to the given time interval, the first value is determined based on a measurement of the parameter corresponding to the given time interval and based on the input from the patient corresponding to the given time interval, and the second value is determined based on a measurement of gastroesophageal contents corresponding to the given time interval; and determine a level of gastrointestinal disorders based on the set of determined value pairs.

The invention discloses construction of a ganoderma spore core-polysaccharide shell double-layer hydrogel ball system and application of the ganoderma spore core-polysaccharide shell double-layer hydrogel ball system in delivery of protein drugs. The delivery carrier in the form of hydrogel balls prepared by the invention maintains more than 90% of protein integrity during preparation and storage, and effective stability is proved; it is proved for the first time that the ganoderma spore-polysaccharide delivery carrier can be used as a multifunctional food-grade platform to stably deliver protein in different gastrointestinal tract delivery scenes.

The invention provides a compound preparation containing curcumin nano-particles as well as a preparation method and application of the compound preparation. Curcumin is wrapped by alcohol-soluble protein to form nano-particles, and the nano-particles are used as a Pickering milk solid emulsifier for emulsifying and dispersing vitamin D and olive oil into an oil phase to form a stable droplet structure; furthermore, polysaccharide with enteric characteristics is used as a water-phase carrier material, and the emulsion is encapsulated in the pellet by using a hole sharpening-solidification method, so that the solidification of the liquid medicine (the emulsion) is realized; the three natural components, namely the curcumin, the vitamin D and the olive oil, are ingeniously integrated into a whole; the targeting property of the medicine at the colon part is improved; meanwhile, the destructive effect of the gastrointestinal tract environment on the medicine carrying nanoparticles is reduced.

A method for treating a gastrointestinal condition includes preparing an aqueous extract of bioactive compound by adding dried green tea material to hot water and filtering the aqueous extract; adding a solution of an iron-containing compound to the filtered aqueous extract to form a complex or chelate of the bioactive compounds with iron; and drying the solution at a temperature between 80 to 150 degrees Fahrenheit to obtain a fine granular or powdered state.

The present invention provides a method of reducing the likelihood of a subject having graft versus host disease or a method of treating graft versus host disease in a subject comprising analyzing a gastrointestinal biopsy of the subject to measure the number and density proportion of cells and administering to the subject a pharmaceutically effective amount of one or more immunosuppressive agents.

A method for treating conditions of the gastrointestinal tract of a subject using a vibrating ingestible capsule ingested by the subject and activated in a targeted zone of the gastrointestinal tract of the subject. The conditions may include a sensation of gastric bloating, a sensation of straining during defecating, diarrhea and / or gastroparesis. The method is further suitable for reducing Bristol stool scores of fecal matter of the subject and for increasing a Bristol stool score of fecal matter of the subject.

According to aspects of the present disclosure, a system includes at least one processor and at least one memory storing instructions that, when executed by the processor(s), cause the system to: obtain images of a portion of a gastrointestinal tract (GIT) captured by a capsule endoscopy device; for each of the images, provide, by a deep learning neural network, a score classifying the image into each of successive segments of the GIT; classify each image of a subset of the images for which the score meets a confidence criterion into one of the successive segments of the GIT; refine the classification of the images in the subset by processing signals corresponding to the classification of the images in the subset over time; and estimate, among the images in the subset, a transition between two adjacent segments of the GIT based on the refined classification of the images in the subset (1010).

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

Methods of treating, reducing the risk of, preventing, or alleviating a symptom of inflammation or inflammatory gastrointestinal disease by administration of a modified bacterium providing purines, in particular hypoxanthine, to the mucosa of the intestine, and compositions containing modified bacteria useful in such methods.

To provide alternative methods of administration of IL-22, since currently there are limitations for administration of IL-22 for treatment of inflammatory diseases.SOLUTION: Provided is an oral, intra-rectal, or other gut-related pharmaceutical composition comprising an IL- 22 protein and an absorption enhancer selected from the group consisting of N(8-[2- hydroxybenzoyl]aino)caprylic acid (NAC), N-(10-[2-hydroxybenzoyl]amino)decanoic acid (NAD), a salt of the NAC or the NAD.SELECTED DRAWING: Figure 1

Systems and methods for objective evaluation of a stool sample to determine whether a patient's lower gastrointestinal tract is sufficiently clean to undergo a successful gastrointestinal visualization procedure with favorable visualization. A method includes collecting a stool sample from a patient and assessing the stool sample to determine whether an intestine of the patient is sufficiently clean for the patient to undergo a successful lower gastrointestinal tract visualization procedure.

The invention belongs to the technical field of medicines, and discloses a betahistine mesylate oral soluble film agent for treating meniere disease, meniere syndrome and vertigo symptoms caused by vertigo and a preparation process thereof, the preparation process comprises the following steps: (1) adding betahistine mesylate into purified water; (2) adding glycerol, citric acid, sucralose, liquid orange-flavored essence and sunset yellow into the raw material medicine solution; (3) taking HPMC-E15, dispersing the HPMC-E15 in purified water, and adding HPC-LXF for thickening; (4) adding the medicine-containing solution into the blank glue solution; (5) degassing; (6) coating; and (7) cutting and packaging. Compared with a common tablet, the oral soluble film disclosed by the invention has a higher release rate, and can enter a body through a sublingual vein way in addition to a conventional gastrointestinal tract absorption way after being dissolved in an oral cavity, so that the bioavailability is increased; under the condition of stability acceleration, the compound has a better impurity level, and the preparation process is simple to operate, high in repeatability and suitable for industrial large-scale production.

The invention provides an ICU patient gastrointestinal complication risk prediction method and system based on time sequence data and a neural network. The method comprises the following steps: collecting time sequence physiological monitoring, static clinical and medical event data with timestamps of a patient, and constructing a dynamic time sequence knowledge graph in real time to represent clinical state evolution; map semantic embedding features are extracted from the map and fused with time sequence dynamic features extracted from the physiological data and static risk features extracted from the static data, and the fusion process is guided by map entity association; historical data and the corresponding atlas are used for training the risk prediction model, and atlas attenuation type label propagation based on atlas association is carried out on training labels according to the atlas structure and the time sequence path during training so as to optimize parameters; and inputting real-time data of a patient to be predicted into the trained model, and outputting a risk prediction result of gastrointestinal complications in a future time window. According to the method, the dynamic knowledge graph and deep learning are fused, and the accuracy and interpretability of risk prediction are improved.

The disclosure generally relates to ready to drink electrolyte solution. In particular the disclosure relates to a ready to drink electrolyte solution comprising isomaltulose, glucose, sodium ions, chromium ions and water; wherein the glucose concentration is greater than or equal to 0.9g / 100ml, and wherein the theoretical glycemic index of the solution is equal to or less than 55. The disclosure also relates to a method of manufacturing said ready to drink electrolyte solution. The disclosure also relates to a method of rehydrating a patient suffering from cancer, diabetes, acute or chronic illness, or a gastrointestinal disorder by using said ready to drink electrolyte solution.

The disclosure is directed to methods for culturing, transferring, and maintaining a microbiota containing a predominance of a select group of beneficial microorganisms to alleviate and / or treat gut dysbiosis, including gastrointestinal symptoms thereof, in a subject suffering from dysbiosis.

The invention belongs to the technical field of medical instruments, and discloses a gastrointestinal tract magnetic clipping fistulization assembly and application thereof. The assembly comprises at least two magnetic bodies, each magnetic body is provided with a clamping end face, the effective length of each clamping end face is 3-5 cm, the width of each clamping end face is not smaller than 0.2 cm, and a clamping gap of 2-4 mm is formed between the stomach wall and the intestinal wall when the two magnetic bodies are attracted. The assembly can adopt an integral structure, a split structure, a bendable structure or a concave-convex clamping structure, and the magnetic body is provided with a fixing structure and a guide assembly. Laparotomy and minimally invasive implantation are not needed, permanent foreign matter residues are avoided, a stable permanent anastomosis channel can be formed, the risk of complications such as adhesion and leakage is reduced, the device is suitable for patients with refractory digestive tract obstruction, and fistulization safety and success rate are improved.

The invention discloses a lactoferrin gel carrier, a preparation method thereof and application of the lactoferrin gel carrier in an oral delivery system. The preparation method comprises the following steps: mixing a lactoferrin solution with transglutaminase, and reacting under mild conditions to form a gel network. According to the method, gel which is compact in structure and high in stability is formed through enzyme catalytic crosslinking, the mechanical strength and embedding capacity of the gel are remarkably enhanced, and the method is suitable for embedding multiple active ingredients (such as probiotics, polyphenol and vitamins) sensitive to heat, oxygen or shear force. The obtained gel carrier can effectively isolate oxygen, moisture and adverse processing environments, and the stability of embedded components in processing, storage and transportation is remarkably improved. The carrier can be slowly released in a gastrointestinal tract environment, and active ingredients are prevented from being degraded too early in gastric acid, so that the intestinal absorption rate and the bioavailability of the carrier are improved. The materials used in the invention are natural proteins, are safe and non-toxic, and accord with food and health care product application standards.

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for promoting postoperative gastrointestinal function recovery and application thereof.The composition comprises rheum officinale and mangnolia officinalis which serve as active ingredients, and the weight ratio of the rheum officinale to the mangnolia officinalis is (1.5-3): 1. Wherein the rhubarb is used as the monarch material and has the functions of purging, removing food retention and cleaning intestines and viscera; the mangnolia officinalis is used as a ministerial drug for promoting qi circulation and relieving distension and restricting the cold property of rheum officinale; the medicine is applied to specific acupuncture points such as Tianshu and Zusanli, so that the dual effects of directly reaching the effect of the medicine to an affected area and regulating meridians and collaterals are realized. Compared with oral administration, the traditional Chinese medicine composition can remarkably promote postoperative borborygmus recovery, shorten the first-time exhaust and defecation time, effectively relieve abdominal distension, avoid direct stimulation of the medicine to postoperative weak gastrointestinal tracts and provide a safe and effective traditional Chinese medicine external treatment new scheme for rapid postoperative rehabilitation.